ClinicalTrials.gg
Not yet recruitingNCT06776198PTMTOUpdated Jan 24, 2025

Precision Therapy Based on Immune Microenvironment by Transcriptome Sequencing of Osteosarcoma, a Prospective, Multi-cohort Exploratory Clinical Study

An observational study in Osteosarcoma, Transcriptome and Tumor Microenvironment, sponsored by Peking University People's Hospital. Not yet recruiting. Open to participants aged 8 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-01-24.

Sponsored by Peking University People's Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
8 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Osteosarcoma by Peking University People's Hospital — 5 open to participants now, 7 under way, none of them phase 3. Osteosarcoma · Peking University People's Hospital.

Planned enrollment
7th of 14
100 · median 100
Started
2025
with 1 other
Observational
14 of 26
2 open now
Registered
22nd of 26
by date

Among the 26 studies in Osteosarcoma by Peking University People's Hospital, this one is the 7th largest by planned enrollment of the 14 observational ones that give a count, is one of 2 that started in 2025, is one of 14 observational ones, and was the 22nd registered.

Osteosarcoma

488 studies on the registry are indexed under Osteosarcoma; 123 are open to participants now.

Browse Osteosarcoma studies →

Open to participants now

5 of the 26 studies in Osteosarcoma by Peking University People's Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 100 Osteosarcoma studies recruiting now, 41 (41%) set no upper age limit and 55 (55%) stop at 75 or younger; 75 take children under 18; 3 take healthy volunteers.

This study: 8 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Osteosarcoma by Peking University People's Hospital, or all of them as a file.
02

Study summary

Bagaev et al. have identified four tumor microenvironment (TME) subtypes that are conserved across diverse cancers and correlated with immunotherapy response in melanoma, bladder, and gastric cancers. They provided a visual tool revealing the TME subtypes integrated with targetable genomic alterations, which provided a planetary view of each tumor that can aid in oncology clinical decision making. We aim to use this tool to prospectively analyse the biopsy specimens of osteosarcomas to identify their TME subtypes so as to deliver appropriate treatment strategy if these osteosarcomas experience disease progression afterwards. We will compare the past sequencing date stored in PKUPH bank so as to compare the event-free survival(EFS) of these patients to check the Superiority of this method later.

03

Conditions studied

  • Osteosarcoma
  • Transcriptome
  • Tumor Microenvironment
  • Precision Medicine

Browse trials for

Keywords

  • osteosarcoma
  • transcriptome
  • tumor microenviroment
  • precision medicine
04

Who can participate

Ages eligible
8 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Initially treated osteosarcoma

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (i) patients who have been suspected for osteosarcoma with enough clinical or radiographic information;
  • (ii) patients who have evaluable lesions to resect or follow;
  • (iii) patients who are planned to be operate with enough flesh specimens for this study.

Exclusion criteria

Exclusion Criteria:

  • (i) clinical information was not complete;
  • (ii) lost to follow-up.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
100 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Immune-Enriched, Fibrotic Group (IE/F)

    Drug: Chemotherapy

  • Immune-Enriched, Non-Fibrotic Group (IE)

    Drug: Chemotherapy

  • Fibrotic Group (F)

    Drug: Chemotherapy

  • Depleted Group (D)

    Drug: Chemotherapy

Interventions

  • DrugChemotherapy

    Group IE/F: After progression, try LRRC15 ADC + PD-1 inhibitors; Group IE: After progression, try simple anti-PD-1 inhibitors; Group F: After progression, try LRRC15 ADC; Group D: After progression, try B7-H3 ADC or other irrinotecan analogue

06

What researchers measure

Primary outcomes

  1. Event-free Survival (EFS)

    From biopsy to progression/last follow-up

    Time frame: 2 year

Secondary outcomes

  1. Event-free Survival (EFS) for the second time

    From first progression to the second progression/last follow-up

    Time frame: 2 year

Other outcomes

  1. Correlation with some DNA target expression

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Bagaev A, Kotlov N, Nomie K, Svekolkin V, Gafurov A, Isaeva O, Osokin N, Kozlov I, Frenkel F, Gancharova O, Almog N, Tsiper M, Ataullakhanov R, Fowler N. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021 Jun 14;39(6):845-865.e7. doi: 10.1016/j.ccell.2021.04.014. Epub 2021 May 20. PubMed 34019806 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2025; primary completion for Mar 2026, 12 months later.

Of 41 observational studies under Osteosarcoma, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 228. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2025
First posted
Jan 15, 2025
StartEst.
Mar 1, 2025
Primary completionEst.
Mar 1, 2026
CompletionEst.
Jun 1, 2027
Last update
Jan 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06776198
Responsible party
Xie Lu (Musculoskeletal Tumor Center, Peking University People's Hospital) — Principal investigator
First posted
Jan 15, 2025
Start date
Mar 1, 2025 (estimated)
Primary completion
Mar 1, 2026 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Jan 24, 2025

Study contacts

Lu Musculoskeletal Tumor Center of PKUPH, M.D.
Contact
xielu@pkuph.edu.cn
+86-86491437

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion